KINIKSA

Serial Number 87836831
Registration 6555482
700

Registration Progress

Application Filed
Mar 16, 2018
Under Examination
Oct 2, 2018
Approved for Publication
Aug 7, 2018
Published for Opposition
Aug 7, 2018
Registered
Nov 9, 2021

Basic Information

Serial Number
87836831
Registration Number
6555482
Filing Date
March 16, 2018
Registration Date
November 9, 2021
Published for Opposition
August 7, 2018
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Nov 9, 2021
Registration
Registered
Classes
005 042 044

Rights Holder

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC.

83
Address
THIRD FLOOR, 23 OLD BOND STREET
LONDON W1S 4PZ
GB

Ownership History

Kiniksa Pharmaceuticals, Ltd.

Original Applicant
03
Hamilton HM 11 BM

Kiniksa Pharmaceuticals, Ltd.

Owner at Publication
03
Hamilton HM 11 BM

Kiniksa Pharmaceuticals, Ltd.

Original Registrant
03
Hamilton HM 11 BM

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC.

New Owner After Registration #1
83
LONDON GB

Legal Representation

Attorney
Maury M. Tepper, III

USPTO Deadlines

Next Renewal Deadline
854 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-11-09)
Due Date
November 09, 2027
Grace Period Ends
May 09, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

39 events
Date Code Type Description
Apr 11, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 9, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER
Oct 7, 2021 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Oct 6, 2021 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 5, 2021 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Sep 28, 2021 IUAF S USE AMENDMENT FILED
Sep 28, 2021 EISU I TEAS STATEMENT OF USE RECEIVED
Apr 13, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 12, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 12, 2021 EX5G S SOU EXTENSION 5 GRANTED
Mar 30, 2021 EEXT I SOU TEAS EXTENSION RECEIVED
Mar 30, 2021 EXT5 S SOU EXTENSION 5 FILED
Oct 2, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 30, 2020 EX4G S SOU EXTENSION 4 GRANTED
Sep 30, 2020 EXT4 S SOU EXTENSION 4 FILED
Sep 30, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
Mar 31, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 29, 2020 EX3G S SOU EXTENSION 3 GRANTED
Mar 29, 2020 EXT3 S SOU EXTENSION 3 FILED
Mar 29, 2020 EEXT I SOU TEAS EXTENSION RECEIVED
Sep 19, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 17, 2019 EX2G S SOU EXTENSION 2 GRANTED
Sep 17, 2019 EXT2 S SOU EXTENSION 2 FILED
Sep 17, 2019 EEXT I SOU TEAS EXTENSION RECEIVED
Apr 3, 2019 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 1, 2019 EX1G S SOU EXTENSION 1 GRANTED
Apr 1, 2019 EEXT I SOU TEAS EXTENSION RECEIVED
Apr 1, 2019 EXT1 S SOU EXTENSION 1 FILED
Oct 2, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 7, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 7, 2018 PUBO A PUBLISHED FOR OPPOSITION
Jul 18, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 29, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 27, 2018 DOCK D ASSIGNED TO EXAMINER
Mar 30, 2018 TAEA I TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Mar 30, 2018 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 23, 2018 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Mar 22, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 20, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
anti-inflammatories; cardiovascular pharmaceuticals; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders; pharmaceutical preparations for the prevention and treatment of inflammatory diseases and disorders; pharmaceutical preparations for the prevention and treatment of pruritus; pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders; pharmaceutical preparations for the prevention and treatment of cardiac diseases and disorders; pharmaceutical preparations for the prevention and treatment of immune-mediated diseases and disorders; pharmaceutical preparations for the prevention and treatment of rare diseases and disorders
First Use Anywhere: Sep 18, 2019
First Use in Commerce: Sep 18, 2019
Class 042
Research and development in the field of pharmaceuticals
First Use Anywhere: Aug 2, 2021
First Use in Commerce: Aug 2, 2021
Class 044
Providing health information
First Use Anywhere: Aug 2, 2021
First Use in Commerce: Aug 2, 2021

Additional Information

Design Mark
The mark consists of a two-dimensional ring bisected by the word "KINIKSA"; the color gray is intended to show shading or contrast only.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005 042 044